Trial Outcomes Present Vital Blood Sugar Discount
Novo Nordisk mentioned its section 3a PIONEER TEENS trial demonstrated a statistically important discount in blood sugar ranges, with HbA1c declining by 0.83% in comparison with placebo at 26 weeks.
The examine evaluated oral semaglutide in 132 kids and adolescents aged 10-17 and confirmed a security profile per earlier semaglutide trials.
“This confirms that oral semaglutide is an efficient remedy choice for youngsters and adolescents with kind 2 diabetes,” mentioned Martin Holst Lange, chief scientific officer at Novo Nordisk.
The corporate mentioned the trial represents the primary medical examine of an oral GLP-1 receptor agonist remedy on this age group, addressing a big unmet want.
Novo Nordisk expects to file for regulatory approval to develop the label for oral semaglutide within the U.S. and EU within the second half of the yr.
Novo Nordisk Shares Edge Greater
NVO Value Motion: On the time of publication, Novo Nordisk shares are buying and selling 3.66% increased at $39.93, in response to knowledge from Benzinga Professional.
Picture by way of Shutterstock
This content material was partially produced with the assistance of AI instruments and was reviewed and printed by Benzinga editors.
Market Information and Knowledge dropped at you by Benzinga APIs
© 2026 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
So as to add Benzinga Information as your most popular supply on Google, click on right here.